Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804400 | 0.94 | PPARG (0.38) | PPARGCSF1RPPARAPPARDBRD4 | |
| SCHEMBL19804501 | 0.91 | PPARG (0.37) | PPARGCSF1RPPARAPPARDBRD4 | |
| SCHEMBL19804072 | 0.90 | CSF1R (0.40) | PPARGCSF1RPPARACA1CA2 | |
| SCHEMBL19804075 | 0.89 | CSF1R (0.35) | PPARGCSF1RPPARAPPARDBRD4 | |
| SCHEMBL19804396 | 0.87 | PPARG (0.35) | PPARGCSF1RPPARAPPARDCA1 | |
| SCHEMBL19804069 | 0.87 | SLC6A9 (0.39) | PPARGCSF1RPPARAPPARDCA1 | |
| SCHEMBL19804297 | 0.87 | CA1 (0.35) | CA1CA2 | |
| SCHEMBL19804483 | 0.87 | FFAR4 (0.40) | PPARGCSF1RPPARACA1CA2 | |
| SCHEMBL20171737 | 0.86 | TSHR (0.34) | PPARGCSF1RPPARAPPARDCA1 | |
| SCHEMBL19796633 | 0.86 | TSHR (0.34) | PPARGCSF1RPPARAPPARDCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | PPARG 3314/4885CSF1R 3027/4885PPARA 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.